The U.S. Food and Drug Administration authorized emergency use of the Pfizer-BioNTech COVID-19 vaccine Friday for people 16 and older. It is the first COVID-19 vaccine to receive emergency authorization in the United States.
The vaccine is given as two doses three weeks apart. The FDA said the trial data showed it was 95 percent effective in preventing COVID-19 among participants evaluated for efficacy. The agency said it did not yet have evidence on how long protection lasts or whether the vaccine prevents transmission.
The authorization allows distribution to begin while safety monitoring and follow-up continue. Health workers preparing to administer the vaccine will also have to manage the cold storage it requires and plan for patients’ second doses.
Reporting source. Cover photograph: U.S. Food and Drug Administration, public domain. Image reuse terms.